Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Dizai Pharma, a China AstraZeneca JV, Raises $100 Million

publication date: Aug 24, 2020

Dizai Pharma of Wuxi City raised $100 million in an A round led by Lilly Asia Ventures. Dizai was formed in 2017 with AstraZeneca assets that were left over after AstraZeneca closed its Shanghai R&D Center. It was founded as a JV between AstraZeneca and the China Future Industry Investment Fund (FIIF), which contributed $132.5 million for a 50% share. Now, Dizai is moving to Wuxi city, where it will be located next to AZN's Wuxi Life Science Innovation Campus, an incubator with $1 billion in support for young companies. More details....

Stock Symbol: (NYSE: AZN)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.